Mineralys Reports Lorundrostat Reduced Heart Failure Risk Biomarkers In Hypertension Trials

Mineralys Therapeutics reported positive post hoc data from its Phase 3 Launch-HTN and Phase 2b Advance-HTN trials, showing Lorundrostat had favorable effects on heart failure risk biomarkers. The update is supportive for the drug’s clinical profile but is post hoc rather than a new primary endpoint result. The news is positive for the stock, though likely limited in immediate market impact.

Analysis

Mineralys Therapeutics reported positive post hoc data from its Phase 3 Launch-HTN and Phase 2b Advance-HTN trials, showing Lorundrostat had favorable effects on heart failure risk biomarkers. The update is supportive for the drug’s clinical profile but is post hoc rather than a new primary endpoint result. The news is positive for the stock, though likely limited in immediate market impact.